Greenwich rises on immune response data from breast cancer therapy trial

Greenwich Lifesciences

02/04/2025 12:59

**  Shares of cancer therapy developer Greenwich LifeSciences GLSI.O rise 18.8% to $11 premarket

** GLSI says its experimental therapy, GLSI-100, to prevent breast cancer recurrences showed an increased immune response over time in patients during a late-stage study

** The therapy creates an immune response over time, as measured by the increasing injection site reactions with increased vaccinations

     ** Company says in the preliminary data, the patients reported immune response increased over time from baseline through the 4th- to 6th-month vaccinations

** As of last close, stock has fallen 51.4% in the past 12 months

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))